These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 15679619

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Familial clustering of factor VIII and von Willebrand factor levels.
    Kamphuisen PW, Houwing-Duistermaat JJ, van Houwelingen HC, Eikenboom JC, Bertina RM, Rosendaal FR.
    Thromb Haemost; 1998 Feb; 79(2):323-7. PubMed ID: 9493584
    [Abstract] [Full Text] [Related]

  • 24. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH, Kappers-Klunne MC, Leebeek FW, Michiels JJ.
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The interaction of the factor VIII/von Willebrand factor complex with hematin.
    Green D, Furby FH, Berndt MC.
    Thromb Haemost; 1986 Dec 15; 56(3):277-82. PubMed ID: 3105105
    [Abstract] [Full Text] [Related]

  • 28. A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors.
    LeBlanc R, Roy J, Demers C, Vu L, Cantin G.
    Bone Marrow Transplant; 1999 May 15; 23(10):991-6. PubMed ID: 10373063
    [Abstract] [Full Text] [Related]

  • 29. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Clin Appl Thromb Hemost; 2006 Jul 15; 12(3):277-95. PubMed ID: 16959681
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ, Gadisseur A, Budde U, Berneman Z, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Semin Thromb Hemost; 2005 Nov 15; 31(5):577-601. PubMed ID: 16276467
    [Abstract] [Full Text] [Related]

  • 33. Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals.
    Schleef M, Strobel E, Dick A, Frank J, Schramm W, Spannagl M.
    Br J Haematol; 2005 Jan 15; 128(1):100-7. PubMed ID: 15606555
    [Abstract] [Full Text] [Related]

  • 34. von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality.
    Catto AJ, Carter AM, Barrett JH, Bamford J, Rice PJ, Grant PJ.
    Thromb Haemost; 1997 Jun 15; 77(6):1104-8. PubMed ID: 9241740
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Response of factor VIII/von Willebrand factor to intranasal DDAVP in healthy subjects and mild haemophiliacs (with observations in patients with combined deficiency of factors V and VIII).
    Garcia VV, Silva IA, Borrasca AL.
    Thromb Haemost; 1982 Aug 24; 48(1):91-3. PubMed ID: 6813999
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate).
    Stadler M, Gruber G, Kannicht C, Biesert L, Radomski KU, Suhartono H, Pock K, Neisser-Svae A, Weinberger J, Römisch J, Svae TE.
    Biologicals; 2006 Dec 24; 34(4):281-8. PubMed ID: 16500114
    [Abstract] [Full Text] [Related]

  • 39. Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease.
    Favaloro EJ, Kershaw G, McLachlan AJ, Lloyd J.
    Semin Thromb Hemost; 2007 Nov 24; 33(8):745-58. PubMed ID: 18175280
    [Abstract] [Full Text] [Related]

  • 40. Determinants of factor VIII plasma levels in carriers of haemophilia A and in control women.
    Ay C, Thom K, Abu-Hamdeh F, Horvath B, Quehenberger P, Male C, Mannhalter C, Pabinger I.
    Haemophilia; 2010 Jan 24; 16(1):111-7. PubMed ID: 19758307
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.